Extracellular HSP90

dc.contributor.author	Σιδέρα, Κατερίνα	el
dc.contributor.author	Πατσαβούδη, Ευαγγελία	el
dc.date.accessioned	2015-06-07T10:31:34Z
dc.date.available	2015-06-07T10:31:34Z
dc.date.issued	2015-06-07
dc.identifier.uri	http://hdl.handle.net/11400/15449
dc.rights	Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ηνωμένες Πολιτείες	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/us/	*
dc.source	http://www.eurekaselect.com/620/journal/current-signal-transduction-therapy	en
dc.subject	Cancer therapeutics
dc.subject	cell invasion
dc.subject	Extracellular HSP90
dc.subject	Signal transduction
dc.subject	Θεραπευτική καρκίνου
dc.subject	Εισβολή κυττάρου
dc.subject	Εξωκυτταρική HSP90
dc.subject	Μεταγωγή σήματος
dc.title	Extracellular HSP90	en
heal.type	journalArticle
heal.secondaryTitle	an emerging target for cancer therapy	en
heal.classification	Medicine
heal.classification	Technology
heal.classification	Ιατρική
heal.classification	Τεχνολογία
heal.classificationURI	http://id.loc.gov/authorities/subjects/sh00006614
heal.classificationURI	http://zbw.eu/stw/descriptor/10470-6
heal.classificationURI	N/A-Ιατρική
heal.classificationURI	N/A-Τεχνολογία
heal.keywordURI	http://lod.nal.usda.gov/23402
heal.identifier.secondary	DOI: 10.2174/157436209787048739
heal.language	en
heal.access	campus
heal.recordProvider	Σχολή Τεχνολογικών Εφαρμογών. Τμήμα Μηχανικών Βιοϊατρικής Τεχνολογίας Τ.Ε.	el
heal.publicationDate	2009
heal.bibliographicCitation	Sidera, K. and Patsavoudi, E. (2009) Extracellular HSP90: an emerging target for cancer therapy. "Current Signal Transduction Therapy", 4 (1), p. 51-58. Available from: http://www.eurekaselect.com/83713/article [Accessed: 07/06/2015].	en
heal.abstract	Cancer is a genetic disease which progresses from benign to malignant stages through the steady acquisition of genomic mutations in key cell-regulatory genes, namely oncogenes, tumor-suppressors, and stability genes. In many ways cancer is considered as a disease of de-regulated signal transduction. Oncogenic mutations frequently lead to overexpression and/or constitutive activation of signal transduction components, allowing cancer cells to override the controlling mechanisms of signalling networks and acquire the cancer-associated traits known as the six hallmarks of cancer. The molecular chaperone HSP90 is viewed as a key player in the subversion of normal cells toward transformation, since many of its client proteins are linked to signalling pathways, commonly de-regulated during tumorigenesis. Consequently, over the past years HSP90 has emerged as a promising and exciting target for the development of cancer chemotherapeutics and already several HSP90 inhibitors are under clinical evaluation. Recently, a pool of HSP90 was identified at the cell surface, where it was shown to be involved in signalling pathways leading to cell motility and invasion. Independent studies suggest that surface HSP90 could be a promising target for the development of effective anti-metastatic strategies. Thus a need for the development of novel cell-impermeable HSP90 inhibitors is emerging.	en
heal.journalName	Current Signal Transduction Therapy	en
heal.journalType	peer-reviewed
heal.fullTextAvailability	true